imiquimod has been researched along with sirolimus in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Babel, N; Bold, G; Eibl, N; Hammer, MH; Reinke, P; Rosenberger, C; Sefrin, A; Ulrich, C | 1 |
| De Meyer, GR; De Meyer, I; Martinet, W; Schrijvers, DM; Timmermans, JP; Verheye, S | 1 |
| Bürger, C; Diehl, S; Han, YY; Kaufmann, R; Lang, V; Ringel, C; Shirsath, N; Weigert, A; Wolf, P | 1 |
| Lipner, SR | 1 |
| Gao, M; Si, X | 1 |
| Blake, T; Lobo, Y; Wheller, L | 1 |
| Chung, BY; Kang, SY; Kim, HO; Kim, HR; Kim, JC; Park, CW | 1 |
| Jiang, X; Li, X; Liu, L; Yang, L; Zhao, Q | 1 |
4 review(s) available for imiquimod and sirolimus
| Article | Year |
|---|---|
Drug-induced macrophage autophagy in atherosclerosis: for better or worse?
Topics: Aminoquinolines; Animals; Autophagy; Cytokines; Everolimus; Humans; Imiquimod; Macrophages; Mice; Plaque, Atherosclerotic; Sirolimus; Toll-Like Receptor 7; TOR Serine-Threonine Kinases | 2013 |
Topical Adjuncts to Pulsed Dye Laser for Treatment of Port Wine Stains: Review of the Literature.
Topics: Administration, Cutaneous; Aminoquinolines; Clinical Trials as Topic; Combined Modality Therapy; Dermatologic Agents; Humans; Imiquimod; Lasers, Dye; Port-Wine Stain; Randomized Controlled Trials as Topic; Sirolimus; Timolol; Treatment Outcome | 2018 |
Management of multiple trichoepithelioma: A review of pharmacological therapies.
Topics: Adalimumab; Administration, Topical; Anilides; Antineoplastic Agents; Aspirin; Humans; Imiquimod; Lasers, Gas; Neoplasms, Adnexal and Skin Appendage; Pyridines; Sirolimus; Skin Neoplasms; Tretinoin | 2021 |
Pathogenesis of Port-Wine Stains: Directions for Future Therapies.
Topics: Angiopoietin-2; Axitinib; Ephrin-B2; Humans; Imiquimod; Phosphatidylinositol 3-Kinases; Photosensitizing Agents; Port-Wine Stain; Proto-Oncogene Proteins c-akt; Receptor, EphA1; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
4 other study(ies) available for imiquimod and sirolimus
| Article | Year |
|---|---|
Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Graft Rejection; Herpesvirus 8, Human; Humans; Imiquimod; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Sarcoma, Kaposi; Sirolimus | 2008 |
Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice.
Topics: Administration, Topical; Aminoquinolines; Animals; Caspase 14; Dendritic Cells; Disease Models, Animal; Imiquimod; Immunosuppressive Agents; Keratin-10; Keratin-14; Ki-67 Antigen; Langerhans Cells; Lymph Nodes; Macrophages; Membrane Proteins; Mice, Inbred BALB C; Neovascularization, Physiologic; Protein Precursors; Psoriasis; Sirolimus; Skin; TOR Serine-Threonine Kinases | 2017 |
Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo.
Topics: Animals; Cell Proliferation; Cytoskeleton; Down-Regulation; Female; Gene Expression; HEK293 Cells; Humans; Imiquimod; Immunosuppressive Agents; Keratinocytes; Male; MAP Kinase Signaling System; Methylation; Mice; Psoriasis; S Phase Cell Cycle Checkpoints; Sirolimus; TOR Serine-Threonine Kinases; Tropomyosin | 2018 |
Rapamycin Alleviates 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Aggravated Dermatitis in Mice with Imiquimod-Induced Psoriasis-Like Dermatitis by Inducing Autophagy.
Topics: Animals; Autophagy; Cell Differentiation; Cells, Cultured; Cytochrome P-450 CYP1A1; Dermatitis; Gene Expression Regulation; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; NADPH Oxidase 4; NF-E2-Related Factor 2; Polychlorinated Dibenzodioxins; Psoriasis; Receptors, Aryl Hydrocarbon; Sirolimus | 2021 |